ETH Zurich has developed an iron fortification technology using oat protein nanofibrils that carry iron nanoparticles. This plant-based hybrid provides high bioavailability, showing nearly twice the iron absorption rate of standard supplements in clinical studies. The compound is tasteless, colorless, and stable, offering an effective, sensory-friendly solution for addressing global iron deficiency in food and beverage applications.
ETH Zurich researchers have developed a highly bioavailable iron fortification technology utilizing oat protein nanofibrils (OatNF) as a delivery platform for ultrasmall iron nanoparticles. By anchoring iron on these plant-based nanostructures, the system stabilizes the iron—typically in a ferrous state when combined with sodium ascorbate—and significantly improves its absorption in the human body. This development offers a clean, plant-based solution for treating iron deficiency and anemia, which affect billions globally. Unlike conventional iron sulfate supplements, which are often limited by poor absorption and metallic sensory qualities, this hybrid material is tasteless and colorless, allowing for easier integration into various foods and beverages without altering their sensory properties.
The technology is currently at TRL 5. It has moved beyond basic research and laboratory synthesis into successful demonstration in human clinical trials, where it showed superior bioavailability in a cohort of 52 iron-deficient women. The underlying technology has been patented in the USA and Europe, and researchers are currently exploring its application as a dietary supplement.
ETH Zurich is a comprehensive, STEM‑focused public research university within Switzerland’s ETH Domain, recognized for large‑scale, interdisciplinary science and engineering. Industry engages on the Hönggerberg “Science City” campus through co‑located laboratories, prototyping spaces, and collaboration suites, and via a joint translational center with the University of Zurich that links researchers to clinical partners. A Basel campus positions faculty and students alongside one of Europe’s densest pharma‑biotech ecosystems, streamlining sponsored research and talent pipelines. Research is supported by the Swiss National Science Foundation, Innosuisse, and competitive European programs. ETH transfer provides IP management, licensing, and startup support to accelerate commercialization.